Y-mabs' danyelza® (naxitamab-gqgk) for the treatment of high-risk neuroblastoma approved in brazil

New york, may 23, 2023 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the brazilian health regulatory agency, agÊncia nacional de vigilÂncia sanitÁria (“anvisa”) has granted marketing authorization for danyelza (naxitamab-gqgk) 40mg/10ml injection. danyelza will be marketed in brazil by y-mabs' partner adium pharma s.a. (“adium”).
YMAB Ratings Summary
YMAB Quant Ranking